

Title: Pre-diagnostic plasma metabolomics and the risk of exfoliation glaucoma

Authors:

Authors: Jae H. Kang^{1*}, Oana Zeleznik,^{1*} Lisa Frueh,² Jessica Lasky-Su,¹ A. Heather Eliassen,^{1,2} Clary Clish,³ Bernard A. Rosner,^{1,4} Louis R. Pasquale,⁵ Janey L. Wiggs⁶

* contributed equally

¹Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts;

²Departments of Nutrition and Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts;

³Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts;

⁴Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts;

⁵Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New York;

⁶Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts.

Correspondence and reprints:

Jae Hee Kang, ScD
Channing Division of Network Medicine
181 Longwood Avenue
Boston, MA 02114
(TEL): 617-525-2022; (FAX) 617-525-2008
e-mail: njhk@channing.harvard.edu

ABSTRACT

Objective: To identify pre-diagnostic plasma metabolomic biomarkers associated with risk of exfoliation glaucoma (XFG).

Methods: We conducted a metabolomic study using a 1:1 matched nested case-control study design within the Nurses' Health Study (NHS) and Health Professionals Follow-up Study (HPFS). Participants provided blood samples in 1989-'90 (NHS) and 1993-'95 (HPFS); we identified 205 participants who newly developed XFG during follow-up to 2018 (average time to diagnosis from blood draw =11.8 years); XFG was confirmed with medical record review. We profiled plasma metabolites using liquid chromatography-mass spectrometry and identified 379 known metabolites that passed quality control checks. Metabolites were transformed using probit scores for normality. We used multivariable-adjusted logistic regression adjusting for matching factors (such as age, residential latitude, season and time of blood draw), glaucoma family history and other covariates. Metabolite Set Enrichment Analysis was used to identify metabolite classes associated with risk of XFG. Number of effective tests (NEF) and False Discovery Rate (FDR) were used to adjust for multiple comparisons.

Results: Mean age of cases (n=205) at diagnosis was 71 years; 84% were women and >99% were Caucasian; matched controls (n=205) all reported eye exams as of the matched cases' index date. A total of 33 metabolites were nominally significantly associated with XFG risk ($p<0.05$) and 4 metabolite classes were significantly associated ($FDR<0.05$). Overall, adverse associations were observed for the classes of lysophosphatidylcholines ($FDR=0.02$) and phosphatidylethanolamine plasmalogens ($FDR=0.004$). Inverse associations were observed for triglycerides ($FDR<0.001$) and steroid and steroid derivatives ($FDR=0.03$); in particular, the multivariable-adjusted odds ratio for XFG risk associated with each 1 standard deviation increase in plasma cortisone levels was 0.49 (95% CI=0.32-0.74; NEF=0.05). Results did not differ materially by time between blood draw and diagnosis, latitude of residence (< or $\geq 41^\circ$ N latitude), age (< or ≥ 60 years), sex or glaucoma family history.

Conclusions: Four broad classes of metabolites (including steroids such as cortisone and 3 lipid classes) in pre-diagnostic plasma collected almost a decade before diagnosis were associated with XFG risk; these results should be confirmed in future studies.

INTRODUCTION

Exfoliation syndrome (XFS) is a systemic age-related disorder of the extracellular matrix that primarily manifests as accumulation of white or grey flaky deposits in the ocular anterior segment.¹ XFS is the most common identifiable cause of glaucoma (XFG), an irreversible blinding disease, and this systemic disorder has been associated with greater risks of cataract and several systemic diseases.^{2,3}

XFS pathogenesis may involve a stress-induced elastosis characterized by excessive production and abnormal cross-linking of microfibrillar components into fibrillar aggregates (XFM: exfoliation material) in the ocular anterior segment and connective tissues in other organs.^{1,4} XFM contains glycoproteins, proteoglycans, and several elastic fiber components and the cross-linking enzyme, lysyl oxidase-like 1 (LOXL1).⁵ Genome-wide association studies have identified several genetic associations with XFS, including *LOXLI*, a principal genetic risk factor for XFS.⁶ While *LOXLI* variants are very strongly associated with XFS, the same variants are also prevalent in unaffected populations, making this a complex disease involving genetic factors, environmental factors and their interactions.⁷

Given that XFS etiology is poorly understood, we conducted an untargeted metabolomics study to identify potential metabolomic markers for XFS. Metabolomics, which is the profiling of small molecules (metabolites) in the body, is a powerful tool for biomarker discovery. To date, there have been only two other metabolomic studies in XFS/XFG;^{8,9} however, these studies were both relatively small (<35 XFS cases) and cross-sectional in design. In this study, we included 205 cases and 205 matched controls in a nested case-control study of pre-diagnostic circulating plasma metabolites from ~10 years before XFS/XFG diagnosis.

METHODS

Study Population

We conducted a nested case-control study in the Nurses' Health Study (NHS) and Health Professional Follow-up Study (HPFS). In 1976, the NHS began with 121,700 female nurses in the US aged 30–55 years, and in 1986, the HPFS was initiated with 51,529 male US health professionals aged 40–75 years. Participants have responded to biennial questionnaires that updated information on lifestyle and medical conditions, such as glaucoma. Blood samples were collected in 1989–'90 among 32,826 NHS participants and in 1993–'95 among 18,159 HPFS participants. In both cohorts, each participant arranged to have a blood sample drawn and shipped by overnight courier to the laboratory. Samples were processed and aliquots of white blood cell, red blood cell, and plasma were archived in liquid nitrogen freezers ($\leq -130^{\circ}\text{C}$).

XFG cases were diagnosed after blood draw until June 1, 2016 (NHS), or January 1, 2016 (HPFS). Cases of XFG (205 total; 174 women and 31 men) were first identified by self-report of glaucoma and then confirmed by medical record review. Controls were 1:1 matched to cases on: age, sex, ancestry (Scandinavian, Southern-European Caucasian, other Caucasian, others), month and year of blood collection, time of day of blood draw, fasting status (>8 hours or ≤ 8 hours), latitude and longitude of residence as of blood draw, and among women: additional matching on menopausal status and hormone therapy use at blood draw (premenopausal, postmenopausal and hormone therapy use, postmenopausal and no hormone therapy use, missing/ unknown) as well as at diagnosis. For matching factors and additional covariate data adjusted for in statistical models, we used questionnaire data collected as of the blood draw, and if not available, we used biennial questionnaire data prior to the blood sample. The study protocol was approved by the institutional review board of the Brigham and Women's Hospital and Harvard T.H. Chan School of Public Health. The return of the self-administered questionnaire and blood sample was considered as implied consent.

Metabolite profiling

Plasma metabolites were profiled using liquid chromatography tandem mass spectrometry (LC-MS) to measure endogenous, polar metabolites and lipids as described previously¹⁰⁻¹² (Broad Institute of MIT and Harvard University (Cambridge, MA)). Of the 398 unique known metabolites evaluated, we excluded 19 metabolites that did not pass quality control checks (10 that were adversely impacted by delay in blood processing inherent in the archived study samples and 9 metabolites that had coefficients of variation (CVs) >25%),¹³ leaving 379 metabolites for analyses. For metabolites with <10% missing across participant samples, missing values were imputed with 1/2 of the minimum value measured for that metabolite. All metabolites included in the analysis exhibited good within person reproducibility over a 1-year period, indicating that one blood sample provides a reasonable measure of longer-term exposure. The 379 metabolites were assigned a metabolite class based on chemical taxonomy; we evaluated 17 metabolite classes: steroids and steroid derivatives; carnitines; diglycerides; triglycerides; cholesteryl esters; lysophosphatidylethanolamines (LPEs); phosphatidylethanolamines (PEs); lysophosphatidylcholines (LPCs); phosphatidylcholines (PCs); phosphatidylethanolamine plasmalogens (PEPs); phosphatidylcholine plasmalogens (PCPs); organoheterocyclic compounds; ceramides; carboxylic acids and derivatives; organic acids and derivatives; nucleosides, nucleotides, and analogues; sphingomyelins. Metabolite values were transformed to probit scores to scale the metabolite levels to the same range and minimize the influence of skewed distributions on the results.

For the metabolite of homocysteine, which has been previously associated with XFS/XFG,¹⁴⁻¹⁶ we determined the concentration of total homocysteine at the Boston Children's Hospital using an enzymatic assay on the Roche P Modular system (Roche Diagnostics - Indianapolis, IN), using reagents and calibrators from Catch Inc. (Seattle, WA), as homocysteine levels assessed using the metabolomics platform described above did not pass quality control checks. The CVs for both NHS and HPFS samples were <10%.

Statistical analysis

We used conditional logistic regression in Model 1 to evaluate metabolite associations with risk of XFG. For both the individual metabolite level analyses as well as metabolite class analyses, in successive models, we used nested multivariable-adjusted conditional logistic regression adjusting for the matching factors as well as additional important covariates. In Model 2, we adjusted for factors as of blood draw that have a major influence on metabolites: age (years; matching factor), sex, month of blood draw (matching factor), year of blood draw (matching factor), time of blood draw (matching factor), fasting status (>8 hours or less), body mass index (kg/m²), smoking status (never, past, current), physical activity (metabolic equivalents of task / week). In Model 3, we expanded Model 2 by adding established risk factors for XFG: glaucoma family history, ancestry (Scandinavian ancestry, other Caucasian, others), time spent outdoors in the summer during youth,¹⁷ history of non-melanoma skin cancer,¹⁸ latitude of residence¹⁹ and residential population density.²⁰ In Model 4, we added additional XFG risk factors, namely the intakes of dietary folate,²¹ caffeine,²² alcohol and total caloric intake. In Model 5, we further added co-morbidities that have been associated with XFG previously: stroke, heart disease, hypertension, high cholesterol, diabetes, hearing loss and sleep duration.²³⁻²⁵ Finally, in Model 6, we added use of oral or inhaled steroid use, to minimize confounding by a commonly used drug that has been associated with glaucoma.

For analyses of individual metabolites, metabolite values were used as continuous variables (per 1 standard deviation increase) to calculate linear trend p-values. We estimated the odds ratios (OR) and 95% confidence intervals (95% CI) per 1 standard deviation (SD) increase in metabolite levels. For analyses of metabolite classes, Metabolite Set Enrichment Analysis was used to identify metabolite classes associated with risk of XFG. For the evaluation of individual metabolites, “number of effective tests” (NEF)²⁶ was used to adjust for multiple comparisons given the high correlation structure of the metabolomics data; NEF<0.05 was considered statistically significant while metabolites with NEF<0.2 were considered as

candidates worthy of further study given the exploratory nature of the analyses. For the evaluation of metabolite classes, False Discovery Rate (FDR)²⁷ was used; FDR<0.05 was considered statistically significant. All analyses were performed with SAS 9.4 and R 3.4.1.

RESULTS

Study population

Of the 205 cases, 84.9% were female, with a mean age (SD) at blood draw of 59.3 (SD=6.5) years and at diagnosis of 71.1 (SD=7.4) years. Mean follow-up time was 11.8 years. Controls were similar to cases in matching factors. Distributions of XFG risk factors were generally in the expected directions for cases and controls (**Table 1**).

Relation between individual metabolites and XFG

Supplementary eTable 1 presents the association with homocysteine (per 1 SD increase) and XFG; no significant associations were observed across the various models ($p>0.18$; Model 6 OR=1.22 (95% CI=0.90, 1.65)). **Supplementary eTable 2** presents the associations between all of the 379 individual metabolites and XFG, and **Figure 1** shows the main results of the individual metabolite analyses; 33 metabolites among 379 metabolites that were at least nominally significant at $p<0.05$ in any of the models (Model 1 through Model 6) were plotted. In the results from Model 1 (crude model adjusting for matching factors only), 20 metabolites were nominally significant, including acetaminophen, methionine sulfoxide, C16:0 LPE, which were all adversely associated (NEF<0.2); in Model 2, where we more finely adjusted for matching factors (e.g., linear age, fasting status, time of day and season of blood draw and other major determinants of variability in metabolites such as BMI), only 9 metabolites were nominally significant. However, in Model 3 and Model 4, with the addition of XFG established and suspected risk factors related

to greater time spent outdoors and factors that may raise serum homocysteine levels as covariates, we observed that cortisone emerged as an NEF significant metabolite that was strongly inversely associated with XFG risk: Model 4 results for each 1SD difference in cortisone level was OR= 0.51 (95%CI=0.36-0.73; NEF=0.01). Also, in Model 4, gabapentin, an anticonvulsant and nerve pain medication, was adversely associated with XFG at OR=1.90 (95%CI=1.26-2.87; NEF=0.16). With Model 5 to further adjust for co-morbidities and Model 6 with the additional adjustment for the use of oral/inhaled corticosteroids, we observed that the effect estimates were similar for cortisone (OR=0.49 (95%CI=0.32-0.74; NEF=0.05)) and gabapentin (OR=2.21 (95% CI=1.31-3.73; NEF=0.21)).

Relation between metabolite classes and XFG

Figure 2 shows the results of evaluating metabolite classes and XFG; results for all 17 metabolite classes are plotted. Model 1 and Model 2 showed generally similar results with FDR-significant positive associations for LPEs and in Model 2, LPCs, nucleosides, nucleotides and analogues newly emerged as significantly adversely associated metabolite classes while carnitines, and triglycerides were significantly inversely associated. In Model 3 and Model 4, with the addition of XFG risk factors, the adverse associations with LPE and LPCs and inverse associations with triglycerides were robust; cholesteryl esters, PEPs and PCPs newly emerged as NEF significantly adversely associated while steroids and steroid derivatives were NEF significantly inversely associated. In Model 5 and Model 6 to additionally adjust for co-morbidities and oral/inhaled corticosteroids, associations with cholesteryl esters, LPEs and PCPs were no longer significant. In the final model, Model 6, we observed 4 classes that were NEF significant: steroids and steroid derivatives and triglycerides were inversely associated (both NEF=0.02), while various lipid classes of LPCs (NEF= 0.03), and PEPs (NEF= 0.03) were positively associated.

Secondary analyses

To evaluate whether associations differed by subgroups, we assessed whether results varied by age (**eFigure 1**), sex (**eFigure 2**), latitude (**eFigure 3**), time to diagnosis (**eFigure 4**), and history of glaucoma (**eFigure 5**). Results, particularly for cortisone, did not differ by subgroups; however, there was a trend for a stronger inverse association among women (which may be due to the much larger sample size among women) and those living in $<41^{\circ}\text{N}$ in latitude for cortisone. Gabapentin tended to be more strongly associated among those with a family history of glaucoma (OR=3.68 (95%CI=1.50-8.99)) than in those without (OR=1.08 (95%CI=0.85-1.39); **eFigure 5**). In sensitivity analyses excluding those who were diagnosed within 5 years of diagnosis in an attempt to remove those who already may have subclinical disease (**eFigure 6**), we observed that the association with cortisone was similar in magnitude (although it was no longer NEF significant). In sensitivity analyses, 1) we excluded those with another age-related ocular condition, age-related macular degeneration, or those who have ever reported using oral / inhaled corticosteroids (**eFigure 7a**) and 2) we further excluded those with conditions that would indicate treatment with corticosteroids (**eFigure 7b**); we observed that the inverse association results for cortisone were robust (OR=0.50 (95%CI=0.32-0.78) and OR=0.55 (95%CI=0.28-1.08), respectively), indicating that the lower cortisone levels in XFG cases than controls was not explained by corticosteroid use.

DISCUSSION:

In this nested case-control study of pre-diagnostic plasma metabolites in relation to XFG (n=410), with a mean 11.8 years between blood draw and diagnosis, we observed that the metabolite cortisone and the metabolite class of triglycerides was inversely associated with XFG while the lipid classes of LPCs, and PEPs were adversely associated with XFG. Because this study was the first to evaluate the relation between pre-diagnostic plasma metabolites, these findings should be confirmed in future studies.

Two previous studies have investigated the metabolic signature of XFS. Leruez, et al.⁸ found that compared to controls with cataracts (n=18), XFS cases (n=16) showed elevated levels of amino acids and

two carnitines (C8 and C10) but lower levels of neuroprotective spermine and spermidine polyamines, diacyl PC phospholipids (C38:0 and C38:1) and sphingomyelin (C26:1). Myer et al., evaluated metabolites in samples of aqueous humor from those with XFS (n=31; 18 women and 13 men; 29 with cataracts) versus controls (n=25; all men with cataracts) and observed that while creatine and 5-hydroxypentanoate were positively associated, propylene glycol, N(6)-acetyllysine, and 5 amino acids were inversely associated with XFS. Our study results are not directly comparable in that prior studies were cross-sectional studies and samples were collected after diagnosis in XFS cases versus mainly those with cataracts as controls; in contrast, our larger study evaluated pre-diagnostic plasma and those with XFG were matched to those without XFG (regardless of cataract status). Therefore, our results are notable in addressing a major gap by providing data from pre-diagnostic plasma that may reflect metabolic changes occurring early in the XFG disease process.

Cortisone and cortisol. The strongly inverse association between steroids and steroid derivatives, especially cortisone, and XFG was a notable finding. Relatively low levels of cortisone may reflect lower systemic endogenous anti-inflammatory corticosteroid levels that may prevent the disruption of the uveal tract blood-ocular barrier integrity leading to the subsequent formation of XFM.²⁸ Although absolute cortisone levels are unknown, relatively lower levels may also reflect adrenal insufficiency; this may be plausible given that body aches and joint pain are common symptoms,²⁹ and gabapentin and acetaminophen were metabolites that were nominally significantly associated with XFG. Adrenal insufficiency has multiple causes;²⁹ one cause may be the adrenal suppression brought on by exogenous corticosteroid use.³⁰ Indeed, XFG cases had somewhat higher prevalence of corticosteroid use than controls (3.9% versus 2.0%), although the overall prevalence was low. To address this possibility, we conducted sensitivity analyses where we excluded participants who self-reported ever having taken oral or inhaled corticosteroids or had conditions that are treated with them, and we observed similar inverse associations. Furthermore, those with corticosteroid-induced secondary glaucoma were not included in our cases,

making it unlikely that differences in corticosteroid use may be underlying all of the inverse associations with cortisone. The link between adrenal insufficiency and XFG is unclear; however, some speculative reasons for why cortisone may be inversely associated is that some studies³¹⁻³³ though not all,^{31,34} have observed that low cortisone/cortisol may be a marker of greater UV exposure, which has been strongly implicated in the pathogenesis of XFS/XFG.³⁵ Indeed, inverse associations with cortisone appeared to be stronger in the subgroup residing in $\leq 41^\circ$ N latitude, where cortisone levels may be a stronger marker of greater UV exposure. Finally, cortisone/cortisol are glucocorticoids, and higher levels in controls versus cases may indicate that controls may have had more frequent hyperglycemia, and several studies³⁶⁻⁴³ have reported inverse associations between diabetes and XFG. The mechanism underlying this trend is unknown; however, it has been hypothesized that greater glycation of basement membrane components may prevent XFM aggregation.^{39,44} This association warrants further study in relation to XFG.

Lysophosphatidylcholines (LPCs). LPCs are pro-inflammatory and may be involved with glaucoma via LPCs' role in the autotaxin-lysophosphatidic acid pathway in intraocular pressure regulation, although the data has been inconsistent.^{8,45-49} Our results are consistent with other studies of targeted lipidomics that have revealed higher total LPCs in the aqueous humor of eyes with glaucoma, including XFG;^{45,46} however, two POAG metabolomics studies of the aqueous humor observed null associations with LPCs,^{47,48} and Leruez et al.⁸ and another study of LPCs in the optic nerve tissue observed inverse associations.⁴⁹ These discrepancies may be related to LPCs with inflammatory properties being limited to those with shorter and unsaturated fatty acids^{50,51} while LPCs with longer and more saturated fatty acids have been inversely associated with type 2 diabetes⁵² and heart disease.⁵³ In our study, we had stronger associations with longer chain length (C20 and C22) LPCs; thus, it is also possible that higher levels of these long-chain LPCs may be markers of a healthier cardiometabolic profile in cases than controls and thus less frequent hyperglycemia that may be possibly associated with less XFM aggregation.^{39,44}

Phosphatidylethanolamine plasmalogens (PEPs). Although higher PEPs have been associated with lower risk of dementia and cardiovascular disease via antioxidant and neuroprotective mechanisms, higher PEPs have also been observed with greater physical activity,⁵⁴ which may be a marker for greater UV exposure that in turn would increase XFG risk. Also, higher PEPs have been associated with a lower quality diet,⁵⁵⁻⁵⁸ characterized by low whole grains and vegetable intake; such a diet with fewer folate sources would be associated with higher homocysteine levels, which has been frequently observed in XFS.^{15,16,59} Although we observed that modest adverse associations with homocysteine itself was not significantly associated, given that other metabolites such as lower phosphatidylcholines,⁶⁰ lower betaine⁶¹ and higher levels of coffee related metabolites (i.e., 3-methylxanthine and trigonelline)^{62,63} that increase homocysteine were near significant, the dysregulation in the homocysteine pathway may still be important early on in the disease process.

Triglycerides. Higher triglycerides as a metabolite class were significantly inversely associated with XFG, which is in contrast to findings from multiple cross-sectional studies that observed positive associations with XFG.⁶⁴⁻⁶⁸ Although we adjusted for caffeine intake and recreational physical activity, lower triglycerides in cases may be capturing residual information about greater coffee consumption⁶⁹ or lower sedentary behavior and greater physical activity,^{70,71} which are likely associated with higher homocysteine levels and greater UV exposure,⁷² respectively, and higher XFG risk. Also, as higher triglyceride levels are a component of metabolic syndrome, it could also be a proxy for greater hyperglycemia, which may have protective effects against the accumulation of XFM.^{39,44}

A limitation of our data is that our study population was relatively homogenous, with mostly White health professionals; therefore, our findings may not be generalizable to other populations with different race and ethnicity composition. Also, there may have been residual confounding by other unmeasured factors in these results. Our blood samples were collected at one timepoint; however, we have only included metabolites with good correlations for within person stability over at least 1 year. Our study had

several strengths. To our knowledge, this is the first study assessing the associations of pre-diagnostic metabolites and XFG risk. Our study has a relatively large sample size with 205 cases and 205 matched controls. Additional strengths include the detailed covariate information and long follow-up time (mean=11.8 years).

Overall, these results provide new and promising candidates for risk detection biomarkers. Additional population studies evaluating metabolites in pre-diagnostic blood are needed to validate these findings. If confirmed, these markers may be used to identify high-risk participants who can benefit from more frequent eye exams.

ACKNOWLEDGMENTS

This work was supported by NEI R01 EY020928, R01 EY015473 (LRP), NCI UM1 CA186107, U01 CA167552, and an unrestricted challenge grant to Icahn School of Medicine at Mount Sinai, Department of Ophthalmology from Research to Prevent Blindness (LRP). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflicts of Interest: Dr. Pasquale is a consultant to Eyenovia, Twenty twenty and Skye Biosciences. Dr. Wiggs is a consultant to Allergan, Avellino, Editas, Maze, Regenxbio and has received research support from Aerpio.

Table 1. Age and age-standardized characteristics of exfoliation glaucoma cases and their matched controls ^a

	Cases	Controls
<i>Matching factors^b</i>	n=205	n=205
Female, n (%)	174 (84.9)	174 (84.9)
Mean age at blood draw (SD), years	59.3 (6.5)	58.7 (5.9)
Mean years from blood draw to diagnosis / index date (SD)	11.8 (6.4)	11.8 (6.4)
Age at diagnosis / index date (SD), years	71.1 (7.4)	70.5 (7.1)
Scandinavian Caucasian, n (%)	13 (6.3)	14 (6.8)
Time of blood draw of 8:00-9:59 am, n (%)	115 (56.1)	118 (57.6)
Season of blood draw of summer, (n, %)	65 (31.7)	74 (36.1)
Fasting >8h, n (%)	142 (69.6)	172 (83.4)
Mean latitude of residence (SD), °N	39.6 (4.3)	39.7 (4.1)
Mean longitude of residence (SD), °W	81.6 (13.0)	81.7 (12.7)
Among females: current user of postmenopausal hormones as of blood draw, n (%)	59 (37.1)	62 (38.5)
Among females: current user of postmenopausal hormones as of diagnosis / index date, n (%)	52 (32.3)	56 (34.4)
<i>Other risk factors</i>		
Family history of glaucoma, n (%)	45 (22.4)	39 (19.2)
6+ hours/week outdoor sunlight exposure during summers in youth, n (%)	98 (53.3)	85 (47.0)
Non-melanoma skin cancer, n (%)	28 (13.7)	18 (8.8)
Mean caffeine intake (SD), mg/day	299.0 (246.4)	283.1 (247.1)
Mean folate intake (SD), mg/day	436.2 (229.3)	427.7 (244.5)
Mean alcohol intake (SD), g/day	6.9 (10.1)	6.4 (9.9)
Mean caloric intake (SD), kcal/day	1806.5 (528.2)	1815.3 (516.7)
Mean body mass index (SD), kg/m ²	24.9 (4.3)	24.9 (4.0)
Mean pack-years of smoking (SD)	10.4 (15.5)	10.1 (15.4)
Mean physical activity (SD), MET-hours per week	21.3 (25.2)	18.9 (20.3)
Mean sleep duration (SD), hours	6.9 (0.9)	7.0 (0.9)
Mean population density (SD) of census tract, number/km ²	1156.8 (1913.7)	1092.6 (1264.0)
Age related macular degeneration	3 (1.5)	3 (1.5)
Hypertension, n (%)	47 (22.9)	61 (29.8)
Hyperlipidemia, n (%)	65 (31.7)	77 (37.6)
Heart disease, n (%)	3 (1.5)	8 (3.9)
Stroke, n (%)	5 (2.4)	0 (0.0)
Diabetes, n (%)	4 (2.0)	5 (2.4)
Hearing loss, n (%)	17 (8.3)	13 (6.3)
Ever used oral or inhaled steroids, n (%)	8 (3.9)	4 (2.0)

Abbreviation: MET=metabolic equivalent of task; SD=standard deviation

^a Values are means \pm SD or percentages, are standardized to the age distribution of the study population and based on those with non-missing values.

^b The cases and controls were 1:1 matched based on age (all >40 years), menopausal status and PMH use at blood collection and diagnosis, month/year/time of day of blood collection, fasting status, ancestry (Scandinavian, S. European, Other Caucasian, other), latitude and longitude as of blood draw, and sample problem type. All cases and controls reported eye exams in the index period of the matched cases' diagnosis date.




Figure 1. Individual metabolites among the n=379 metabolites evaluated that were significant across the various nested multiple conditional logistic regression models of exfoliation glaucoma (205 cases and 205 controls). **Model 1**: basic model, adjusting for matching factors only (see Table 1); **Model 2** (factors that affect metabolite levels): Model 1 + age, sex, smoking status, BMI, physical activity, time of day of blood draw, month of blood draw, fasting status; **Model 3** (presumed exfoliation syndrome risk factors): Model 2 + type of Caucasian, family history of glaucoma, time spent outdoors in sunlight in the summer in youth, non-melanoma skin cancer, latitude, population density; **Model 4** (factors that may raise homocysteine levels): Model 3 + folate intake, caffeine intake, alcohol intake, caloric intake; **Model 5** (systemic comorbidities suggested to be associated with XFS in some studies): Model 4 + heart disease, stroke, diabetes, hypertension, high cholesterol, hearing loss, sleep duration; **Model 6** (use of drugs associated with glaucoma): Model 5 + steroid use. * p<0.05; ** Number of effective tests (NEF)<0.2; *** NEF<0.05




Figure 2. Metabolite classes (n=17) evaluated in various nested multiple conditional logistic regression models of exfoliation glaucoma (205 cases and 205 controls). **Model 1**: basic model, adjusting for matching factors only (see Table 1); **Model 2** (factors that affect metabolite levels): Model 1 + age, sex, smoking status, BMI, physical activity, time of day of blood draw, month of blood draw, fasting status; **Model 3** (presumed exfoliation syndrome risk factors): Model 2 + type of Caucasian, family history of glaucoma, time spent outdoors in sunlight in the summer in youth, non-melanoma skin cancer, latitude, population density; **Model 4** (factors that may raise homocysteine levels): Model 3 + folate intake, caffeine intake, alcohol intake, caloric intake; **Model 5** (systemic comorbidities suggested to be associated with XFS in some studies): Model 4 + heart disease, stroke, diabetes, hypertension, high cholesterol, hearing loss, sleep duration; **Model 6** (use of drugs associated with glaucoma): Model 5 + steroid use. ** False Discovery Rate (FDR)<0.2; *** FDR<0.05.

References

1. Ritch R, Schlotzer-Schrehardt U. Exfoliation syndrome. *Surv Ophthalmol*. 2001;45(4):265-315.
2. Anastasopoulos E, Founti P, Topouzis F. Update on pseudoexfoliation syndrome pathogenesis and associations with intraocular pressure, glaucoma and systemic diseases. *Curr Opin Ophthalmol*. 2015;26(2):82-89.
3. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. *Ophthalmology*. 2014;121(11):2081-2090.
4. Schlotzer-Schrehardt U. Molecular Biology of Exfoliation Syndrome. *J Glaucoma*. 2018;27 Suppl 1:S32-S37.
5. Zenkel M, Schlotzer-Schrehardt U. The composition of exfoliation material and the cells involved in its production. *J Glaucoma*. 2014;23(8 Suppl 1):S12-14.
6. Schlotzer-Schrehardt U. Genetics and genomics of pseudoexfoliation syndrome/glaucoma. *Middle East Afr J Ophthalmol*. 2011;18(1):30-36.
7. Dewundara S, Pasquale LR. Exfoliation syndrome: a disease with an environmental component. *Curr Opin Ophthalmol*. 2015;26(2):78-81.
8. Leruez S, Bresson T, Chao de la Barca JM, et al. A Plasma Metabolomic Signature of the Exfoliation Syndrome Involves Amino Acids, Acylcarnitines, and Polyamines. *Invest Ophthalmol Vis Sci*. 2018;59(2):1025-1032.
9. Myer C, Abdelrahman L, Banerjee S, et al. Aqueous humor metabolite profile of pseudoexfoliation glaucoma is distinctive. *Mol Omics*. 2020;16(5):425-435.
10. Vardhan SA, HariPriya A, Ratukondla B, et al. Association of Pseudoexfoliation With Systemic Vascular Diseases in a South Indian Population. *JAMA Ophthalmol*. 2017;135(4):348-354.
11. O'Sullivan JF, Morningstar JE, Yang Q, et al. Dimethylguanidino valeric acid is a marker of liver fat and predicts diabetes. *J Clin Invest*. 2017;127(12):4394-4402.
12. Mascanfroni ID, Takenaka MC, Yeste A, et al. Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1- α . *Nat Med*. 2015;21(6):638-646.
13. Townsend MK, Clish CB, Kraft P, et al. Reproducibility of metabolomic profiles among men and women in 2 large cohort studies. *Clin Chem*. 2013;59(11):1657-1667.
14. Cumurcu T, Sahin S, Aydin E. Serum homocysteine, vitamin B 12 and folic acid levels in different types of glaucoma. *BMC Ophthalmol*. 2006;6:6.
15. Roedl JB, Bleich S, Reulbach U, et al. Vitamin deficiency and hyperhomocysteinemia in pseudoexfoliation glaucoma. *J Neural Transm*. 2007;114(5):571-575.
16. Xu F, Zhang L, Li M. Plasma homocysteine, serum folic acid, serum vitamin B12, serum vitamin B6, MTHFR and risk of pseudoexfoliation glaucoma: a meta-analysis. *Graefes Arch Clin Exp Ophthalmol*. 2012;250(7):1067-1074.
17. Kang JH, Wiggs JL, Pasquale LR. Relation between time spent outdoors and exfoliation glaucoma or exfoliation glaucoma suspect. *Am J Ophthalmol*. 2014;158(3):605-614 e601.
18. Kang JH, VoPham T, Laden F, et al. Cohort Study of Nonmelanoma Skin Cancer and the Risk of Exfoliation Glaucoma. *J Glaucoma*. 2020;29(6):448-455.
19. Kang JH, Loomis S, Wiggs JL, Stein JD, Pasquale LR. Demographic and geographic features of exfoliation glaucoma in 2 United States-based prospective cohorts. *Ophthalmology*. 2012;119(1):27-35.
20. Taylor HR. Pseudoexfoliation, an environmental disease? *Trans Ophthalmol Soc U K*. 1979;99(2):302-307.

21. Kang JH, Loomis SJ, Wiggs JL, Willett WC, Pasquale LR. A prospective study of folate, vitamin B(6), and vitamin B(1)(2) intake in relation to exfoliation glaucoma or suspected exfoliation glaucoma. *JAMA Ophthalmol.* 2014;132(5):549-559.
22. Pasquale LR, Wiggs JL, Willett WC, Kang JH. The Relationship between caffeine and coffee consumption and exfoliation glaucoma or glaucoma suspect: a prospective study in two cohorts. *Invest Ophthalmol Vis Sci.* 2012;53(10):6427-6433.
23. Bikbov MM, Zainullin RM, Gilmanshin TR, et al. Prevalence and Associated Factors of Pseudoexfoliation in a Russian Population: The Ural Eye and Medical Study. *Am J Ophthalmol.* 2020;210:158-166.
24. Zehavi-Dorin T, Nahum N, Ben-Artzi E, Levkovitch-Verbin H. Exfoliation syndrome: association with systemic diseases-the Maccabi glaucoma study. *Graefes Arch Clin Exp Ophthalmol.* 2021.
25. Rumelaitiene U, Zaliuniene D, Speckauskas M, et al. Link of ocular pseudoexfoliation syndrome and vascular system changes: results from 10-year follow-up study. *Int Ophthalmol.* 2020;40(4):957-966.
26. Gao X, Starmer J, Martin ER. A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. *Genet Epidemiol.* 2008;32(4):361-369.
27. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Statist Soc B.* 1995;57(1):289-300.
28. Kuchle M, Nguyen NX, Hannappel E, Naumann GO. The blood-aqueous barrier in eyes with pseudoexfoliation syndrome. *Ophthalmic Res.* 1995;27 Suppl 1:136-142.
29. Martin-Grace J, Dineen R, Sherlock M, Thompson CJ. Adrenal insufficiency: Physiology, clinical presentation and diagnostic challenges. *Clin Chim Acta.* 2020;505:78-91.
30. Nicolaides NC, A.N. P, Maria Alexandra MA, Chrousos GP. Glucocorticoid Therapy and Adrenal Suppression. . MDText.com, Inc. Endotext Web site. <https://www.ncbi.nlm.nih.gov/books/NBK279156/>. Published 2000-. Updated 10/19/2018. Accessed 7/25/2021, 2021.
31. Jung CM, Khalsa SB, Scheer FA, et al. Acute effects of bright light exposure on cortisol levels. *J Biol Rhythms.* 2010;25(3):208-216.
32. Kostoglou-Athanassiou I, Treacher DF, Wheeler MJ, Forsling ML. Bright light exposure and pituitary hormone secretion. *Clin Endocrinol (Oxf).* 1998;48(1):73-79.
33. Hadlow NC, Brown S, Wardrop R, Henley D. The effects of season, daylight saving and time of sunrise on serum cortisol in a large population. *Chronobiol Int.* 2014;31(2):243-251.
34. Thalen BE, Morkrid L, Kjellman BF, Wetterberg L. Cortisol in light treatment of seasonal and non-seasonal depression: relationship between melatonin and cortisol. *Acta Psychiatr Scand.* 1997;96(5):385-394.
35. Pasquale LR, Borrás T, Fingert JH, Wiggs JL, Ritch R. Exfoliation syndrome: assembling the puzzle pieces. *Acta Ophthalmol.* 2016;94(6):e505-512.
36. Konstas AG, Tsatsos I, Kardasopoulos A, Bufidis T, Maskaleris G. Preoperative features of patients with exfoliation glaucoma and primary open-angle glaucoma. The AHEPA study. *Acta Ophthalmol.* 1998;76(2):208-212.
37. Wood SD, Asefzadeh B, Fisch B, et al. The relationship between diabetes mellitus and exfoliation syndrome in a United States Veterans Affairs population: a case-control study. *J Glaucoma.* 2011;20(5):278-281.
38. Tarkkanen A, Reunanen A, Kivela T. Frequency of systemic vascular diseases in patients with primary open-angle glaucoma and exfoliation glaucoma. *Acta Ophthalmol.* 2008;86(6):598-602.
39. Tarkkanen A. Is exfoliation syndrome a sign of systemic vascular disease? *Acta Ophthalmol.* 2008;86(8):832-836.

40. Psilas KG, Stefaniotou MJ, Aspiotis MB. Pseudoexfoliation syndrome and diabetes mellitus. *Acta Ophthalmol.* 1991;69(5):664-666.
41. Miyazaki M, Kubota T, Kubo M, et al. The Prevalence of Pseudoexfoliation Syndrome in a Japanese Population: The Hisayama Study. *J Glaucoma.* 2005;14(6):482-484.
42. Shingleton BJ, Heltzer J, O'Donoghue MW. Outcomes of phacoemulsification in patients with and without pseudoexfoliation syndrome. *J Cataract Refract Surg.* 2003;29(6):1080-1086.
43. Jonas JB, Gründler AE. Prevalence of diabetes mellitus and arterial hypertension in primary and secondary open-angle glaucomas. *Graefe's Archive for Clinical and Experimental Ophthalmology.* 1998;236(3):202-206.
44. Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. *Korean J Physiol Pharmacol.* 2014;18(1):1-14.
45. Ho LTY, Osterwald A, Ruf I, et al. Role of the autotaxin-lysophosphatidic acid axis in glaucoma, aqueous humor drainage and fibrogenic activity. *Biochim Biophys Acta Mol Basis Dis.* 2020;1866(1):165560.
46. Honjo M, Igarashi N, Kurano M, et al. Autotaxin-Lysophosphatidic Acid Pathway in Intraocular Pressure Regulation and Glaucoma Subtypes. *Invest Ophthalmol Vis Sci.* 2018;59(2):693-701.
47. Pan CW, Ke C, Chen Q, et al. Differential metabolic markers associated with primary open-angle glaucoma and cataract in human aqueous humor. *BMC Ophthalmol.* 2020;20(1):183.
48. Buisset A, Gohier P, Leruez S, et al. Metabolomic Profiling of Aqueous Humor in Glaucoma Points to Taurine and Spermine Deficiency: Findings from the Eye-D Study. *J Proteome Res.* 2019;18(3):1307-1315.
49. Milbeck SM, Bhattacharya SK. Alteration in Lysophospholipids and Converting Enzymes in Glaucomatous Optic Nerves. *Invest Ophthalmol Vis Sci.* 2020;61(6):60.
50. Law SH, Chan ML, Marathe GK, Parveen F, Chen CH, Ke LY. An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases. *Int J Mol Sci.* 2019;20(5).
51. Liu P, Zhu W, Chen C, et al. The mechanisms of lysophosphatidylcholine in the development of diseases. *Life Sci.* 2020;247:117443.
52. Floegel A, Stefan N, Yu Z, et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. *Diabetes.* 2013;62(2):639-648.
53. Park JY, Lee SH, Shin MJ, Hwang GS. Alteration in metabolic signature and lipid metabolism in patients with angina pectoris and myocardial infarction. *PLoS One.* 2015;10(8):e0135228.
54. Ding M, Zeleznik OA, Guasch-Ferre M, et al. Metabolome-Wide Association Study of the Relationship Between Habitual Physical Activity and Plasma Metabolite Levels. *Am J Epidemiol.* 2019;188(11):1932-1943.
55. Bagheri M, Willett W, Townsend MK, et al. A lipid-related metabolomic pattern of diet quality. *The American Journal of Clinical Nutrition.* 2020;112(6):1613-1630.
56. Hernández-Alonso PA-O, Becerra-Tomás N, Papandreou C, et al. Plasma Metabolomics Profiles are Associated with the Amount and Source of Protein Intake: A Metabolomics Approach within the PREDIMED Study. (1613-4133 (Electronic)).
57. Chandler PD, Balasubramanian R, Paynter N, et al. Metabolic signatures associated with Western and Prudent dietary patterns in women. (1938-3207 (Electronic)).
58. Rebholz CA-O, Gao Y, Talegawkar S, et al. Metabolomic Markers of Southern Dietary Patterns in the Jackson Heart Study. (1613-4133 (Electronic)).
59. Bleich S, Roedel J, Von Ahnen N, et al. Elevated homocysteine levels in aqueous humor of patients with pseudoexfoliation glaucoma. *Am J Ophthalmol.* 2004;138(1):162-164.

60. Olthof MR, Brink EJ, Katan MB, Verhoef P. Choline supplemented as phosphatidylcholine decreases fasting and postmethionine-loading plasma homocysteine concentrations in healthy men. *Am J Clin Nutr*. 2005;82(1):111-117.
61. Olthof MR, Verhoef P. Effects of betaine intake on plasma homocysteine concentrations and consequences for health. (1389-2002 (Print)).
62. Beaudoin MS, Graham TE. Methylxanthines and human health: epidemiological and experimental evidence. (0171-2004 (Print)).
63. Christensen B, Mosdol A Fau - Retterstol L, Retterstol L Fau - Landaas S, Landaas S Fau - Thelle DS, Thelle DS. Abstention from filtered coffee reduces the concentrations of plasma homocysteine and serum cholesterol--a randomized controlled trial. (0002-9165 (Print)).
64. Mirza E. Atherogenic indices in pseudoexfoliation syndrome. *Eye (Lond)*. 2019;33(12):1911-1915.
65. Turkyilmaz K, Oner V, Kirbas A, et al. Serum YKL-40 levels as a novel marker of inflammation and endothelial dysfunction in patients with pseudoexfoliation syndrome. *Eye (Lond)*. 2013;27(7):854-859.
66. Janicijevic K, Kocic S, Pajovic S, Zdravkovic N, Sarenac-Vulovic T, Janicijevic-Petrovic M. The importance of developing atherosclerosis in pseudoexfoliation glaucoma. *Vojnosanit Pregl*. 2017;74(1):8-12.
67. Lesiewska H, Lukaszewska-Smyk A, Odrowaz-Sypniewska G, Krintus M, Mankowska-Cyl A, Malukiewicz G. Chosen Vascular Risk Markers in Pseudoexfoliation Syndrome: An Age-Related Disorder. *Journal of ophthalmology*. 2017;2017:5231095.
68. Yilmaz N, Coban DT, Bayindir A, et al. Higher serum lipids and oxidative stress in patients with normal tension glaucoma, but not pseudoexfoliative glaucoma. *Bosn J Basic Med Sci*. 2016;16(1):21-27.
69. Hang D, Zeleznik OA, He X, et al. Metabolomic Signatures of Long-term Coffee Consumption and Risk of Type 2 Diabetes in Women. *Diabetes Care*. 2020;43(10):2588-2596.
70. Crichton GE, Alkerwi A. Physical activity, sedentary behavior time and lipid levels in the Observation of Cardiovascular Risk Factors in Luxembourg study. *Lipids Health Dis*. 2015;14:87.
71. Healy GN, Matthews CE, Dunstan DW, Winkler EA, Owen N. Sedentary time and cardio-metabolic biomarkers in US adults: NHANES 2003-06. *Eur Heart J*. 2011;32(5):590-597.
72. Solis-Urra P, Cristi-Montero C, Romero-Parra J, Zavala-Crichton JP, Saez-Lara MJ, Plaza-Diaz J. Passive Commuting and Higher Sedentary Time Is Associated with Vitamin D Deficiency in Adult and Older Women: Results from Chilean National Health Survey 2016(-)2017. *Nutrients*. 2019;11(2).